


**IN THE CLAIMS**

1-24. (Canceled)

25. (Previously Presented) A method for treating retinopathy, age-related macular degeneration or glaucoma comprising administering to a mammal in need of such treatment an effective amount of a compound of formula X



or an enantiomer or a pharmaceutically acceptable equivalent of said compound, wherein:

$X^3$  is  $-(CR^{36}R^{37})_nSH$ ,  $-O(CR^{36}R^{37})_2SH$ ,  $-S(CR^{36}R^{37})_2SH$  or  $-NR(CR^{36}R^{37})_2SH$ ;

$n$  is 1-3; and

$R$ ,  $R^{36}$ ,  $R^{37}$ ,  $A^6$ ,  $A^7$ ,  $A^8$  and  $A^9$  are independently hydrogen,  $C_1$ - $C_9$  alkyl,  $C_2$ - $C_9$  alkenyl,  $C_2$ - $C_9$  alkynyl, aryl, heteroaryl, carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino, cyano, isocyano, thiocyno, isothiocyno, formamido, thioformamido, sulfo, sulfinio,  $C_1$ - $C_9$  alkylsulfonyl,  $C_1$ - $C_9$  alkoxy,  $C_2$ - $C_9$  alkenoxy, phenoxy and benzyloxy, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenoxy, phenoxy and benzyloxy are independently unsubstituted or substituted with one or more substituent(s).

26. (Previously Presented) The method of claim 25, wherein the compound of formula X is selected from the group consisting of:

3-(2-mercaptoethyl)-benzoic acid;

3-(mercaptomethyl)-benzoic acid;

2-(mercaptomethyl)-benzoic acid;

5-hydroxy-2-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-benzoic acid;

5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-5-(phenylmethoxy)-benzoic acid;

2-(carboxymethoxy)-6-(2-mercaptoethyl)-benzoic acid;  
5-[(3-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-(phenylmethoxy)-benzoic acid;  
2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid;  
2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-(2-phenylethoxy)-benzoic acid;  
2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-phenoxy-benzoic acid;  
2-(2-mercaptoethyl)-6-phenylamino-benzoic acid;  
2-(2-mercaptoethyl)-6-(phenylthio)-benzoic acid;  
5'-(1,1-dimethylethyl)-3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid;  
3-(2-mercaptoethyl)-[1,1'-biphenyl]-2,4'-dicarboxylic acid;  
2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-carboxy-3-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(3-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(biphenyl-2-ylmethoxy)-6-(2-mercaptoethyl)-benzoic acid;  
2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]-benzoic acid;  
2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]-benzoic acid;  
2-[(4-bromo-3-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
2-[(2-carboxy-5-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;  
5-(mercaptomethyl)-2-(2-phenylethoxy)-benzoic acid;  
2-bromo-5-(mercaptomethyl)-benzoic acid;  
4-(mercaptomethyl)-[1,1'-biphenyl]-2,3'-carboxylic acid;

5-(mercaptomethyl)-2-(phenylmethoxy)-benzoic acid; and  
4-bromo-3(mercaptomethyl)-benzoic acid; and  
enantiomers and pharmaceutically acceptable equivalents.

27-49. (Canceled)

50. (Previously Presented) The method of claim 25, wherein the method is for treating retinopathy.

51. (Previously Presented) The method of claim 50, wherein the retinopathy is diabetic retinopathy.

52. (Previously Presented) The method of claim 25, wherein the method is for treating age-related macular degeneration.

53. (Previously Presented) The method of claim 25, wherein the method is for treating glaucoma.

54. (Previously Presented) The method of claim 26, wherein the method is for treating retinopathy.

55. (Previously Presented) The method of claim 54, wherein the retinopathy is diabetic retinopathy.

56. (Previously Presented) The method of claim 26, wherein the method is for treating age-related macular degeneration.

57. (Previously Presented) The method of claim 26, wherein the method is for treating glaucoma.

58. (Canceled)